NCT04746911 - Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions

PsoriasisPlaque Psoriasis

Interventions

DRUG

ARQ-151 cream 0.3%

ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks

Trial Locations (18)

33125

Arcutis Clinical Study Site 628, Miami

33146

Arcutis Clinical Site 602, Coral Gables

33155

Arcutis Clinical Site 607, Miami

33428

Arcutis Clinical Site 610, Boca Raton

33484

Arcutis Clinical Site 613, Delray Beach

35223

Arcutis Clinical Site 603, Mountain Brook

47906

Arcutis Clinical Site 627, West Lafayette

75034

Arcutis Clinical Site 619, Frisco

Arcutis Clinical Study Site 619, Frisco

76001

Arcutis Clinical Site 606, Arlington

77030

Arcutis Clinical Site 605, Houston

85255

Arcutis Clinical Site 604, Scottsdale

90017

Arcutis Clinical Site 618, Los Angeles

90057

Arcutis Clinical Site 608, Los Angeles

92688

Arcutis Clinical Site 611, Rancho Santa Margarita

92708

Arcutis Clinical Site 609, Fountain Valley

M5G 1X8

Arcutis Clinical Site 621, Toronto

Unknown

Arcutis Clinical Site 630, Santo Domingo